4//SEC Filing
Haqq Christopher 4
Accession 0001209191-18-030722
CIK 0001604464other
Filed
May 15, 8:00 PM ET
Accepted
May 16, 8:37 PM ET
Size
14.8 KB
Accession
0001209191-18-030722
Insider Transaction Report
Form 4
Haqq Christopher
Chief Medical Officer
Transactions
- Sale
Common Stock
2018-05-15$46.02/sh−9,252$425,777→ 332,130 total - Sale
Common Stock
2018-05-15$44.44/sh−6,885$305,969→ 351,020 total - Exercise/Conversion
Common Stock
2018-05-15$11.00/sh+25,000$275,000→ 357,905 total - Sale
Common Stock
2018-05-15$45.21/sh−9,638$435,734→ 341,382 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2018-05-15−25,000→ 25,000 totalExercise: $11.00Exp: 2021-10-15→ Common Stock (25,000 underlying)
Holdings
- 17,312(indirect: See footnote)
Common Stock
- 2,688(indirect: See footnote)
Common Stock
Footnotes (7)
- [F1]Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018.
- [F2]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $43.75 to $44.75. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $44.80 to $45.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F4]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $45.85 to $46.30. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F5]The shares are held by the Chris Haqq 2014 GRAT, of which the Reporting Person is trustee.
- [F6]The shares are held by The Havenside Trust, of which the Reporting Person is trustee.
- [F7]1/48th of the shares subject to the stock option vest and become exercisable each month following October 15, 2014.
Documents
Issuer
Atara Biotherapeutics, Inc.
CIK 0001604464
Entity typeother
Related Parties
1- filerCIK 0001612095
Filing Metadata
- Form type
- 4
- Filed
- May 15, 8:00 PM ET
- Accepted
- May 16, 8:37 PM ET
- Size
- 14.8 KB